← All trials
NCT04907526
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2024
- First posted
- May 28, 2021
- Last posted
- May 28, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- University of ColoradoOverall official - principal investigator
- University of ColoradoCollaborator
- University of TorontoCollaborator
- University of PennsylvaniaOverall official - principal investigator
- University of PennsylvaniaCollaborator
- Mayo ClinicOverall official - principal investigator
- Mayo ClinicCollaborator
- University of Alabama, BirminghamOverall official - principal investigator
- University of MinnesotaCollaborator
- University of CincinnatiOverall official - principal investigator
- University of CincinnatiCollaborator
- University of OklahomaCollaborator
- Ochsner Health SystemOverall official - principal investigator
- Ochsner Health SystemCollaborator
- Children's Hospital Los AngelesOverall official - principal investigator
- Children's Hospital Los AngelesCollaborator
- University of MinnesotaOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- University of Alabama, BirminghamCollaborator
- University of TorontoOverall official - principal investigator
- ReGen Theranostics, Inc.Sponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.